Advances in lipid-based nanocarriers for breast cancer metastasis treatment
Breast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance sev...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Medical Technology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmedt.2022.893056/full |
| _version_ | 1811214663328727040 |
|---|---|
| author | Ingrid Joun Ingrid Joun Sheri Nixdorf Sheri Nixdorf Wei Deng Wei Deng |
| author_facet | Ingrid Joun Ingrid Joun Sheri Nixdorf Sheri Nixdorf Wei Deng Wei Deng |
| author_sort | Ingrid Joun |
| collection | DOAJ |
| description | Breast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance severely affect the quality of life of BC patients. To overcome these limitations, many efforts have been made to develop nanomaterial-based drug delivery systems. Among these nanocarriers, lipid-based delivery platforms represented one of the most successful candidates for cancer therapy, improving the safety profile and therapeutic efficacy of encapsulated drugs. In this review we will mainly discuss and summarize the recent advances in such delivery systems for BC metastasis treatment, with a particular focus on targeting the common metastatic sites in bone, brain and lung. We will also provide our perspectives on lipid-based nanocarrier development for future clinical translation. |
| first_indexed | 2024-04-12T06:08:41Z |
| format | Article |
| id | doaj.art-b8c7000295a84370838e734ba2ccfdf8 |
| institution | Directory Open Access Journal |
| issn | 2673-3129 |
| language | English |
| last_indexed | 2024-04-12T06:08:41Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medical Technology |
| spelling | doaj.art-b8c7000295a84370838e734ba2ccfdf82022-12-22T03:44:47ZengFrontiers Media S.A.Frontiers in Medical Technology2673-31292022-08-01410.3389/fmedt.2022.893056893056Advances in lipid-based nanocarriers for breast cancer metastasis treatmentIngrid Joun0Ingrid Joun1Sheri Nixdorf2Sheri Nixdorf3Wei Deng4Wei Deng5School of Chemical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, AustraliaGraduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, AustraliaGraduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, AustraliaSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Ultimo, NSW, AustraliaGraduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, AustraliaSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Ultimo, NSW, AustraliaBreast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance severely affect the quality of life of BC patients. To overcome these limitations, many efforts have been made to develop nanomaterial-based drug delivery systems. Among these nanocarriers, lipid-based delivery platforms represented one of the most successful candidates for cancer therapy, improving the safety profile and therapeutic efficacy of encapsulated drugs. In this review we will mainly discuss and summarize the recent advances in such delivery systems for BC metastasis treatment, with a particular focus on targeting the common metastatic sites in bone, brain and lung. We will also provide our perspectives on lipid-based nanocarrier development for future clinical translation.https://www.frontiersin.org/articles/10.3389/fmedt.2022.893056/fullbreast cancer metastasisliposomestargeting strategynanomaterial-based drug deliverylipid nanoparticles (LNPs) |
| spellingShingle | Ingrid Joun Ingrid Joun Sheri Nixdorf Sheri Nixdorf Wei Deng Wei Deng Advances in lipid-based nanocarriers for breast cancer metastasis treatment Frontiers in Medical Technology breast cancer metastasis liposomes targeting strategy nanomaterial-based drug delivery lipid nanoparticles (LNPs) |
| title | Advances in lipid-based nanocarriers for breast cancer metastasis treatment |
| title_full | Advances in lipid-based nanocarriers for breast cancer metastasis treatment |
| title_fullStr | Advances in lipid-based nanocarriers for breast cancer metastasis treatment |
| title_full_unstemmed | Advances in lipid-based nanocarriers for breast cancer metastasis treatment |
| title_short | Advances in lipid-based nanocarriers for breast cancer metastasis treatment |
| title_sort | advances in lipid based nanocarriers for breast cancer metastasis treatment |
| topic | breast cancer metastasis liposomes targeting strategy nanomaterial-based drug delivery lipid nanoparticles (LNPs) |
| url | https://www.frontiersin.org/articles/10.3389/fmedt.2022.893056/full |
| work_keys_str_mv | AT ingridjoun advancesinlipidbasednanocarriersforbreastcancermetastasistreatment AT ingridjoun advancesinlipidbasednanocarriersforbreastcancermetastasistreatment AT sherinixdorf advancesinlipidbasednanocarriersforbreastcancermetastasistreatment AT sherinixdorf advancesinlipidbasednanocarriersforbreastcancermetastasistreatment AT weideng advancesinlipidbasednanocarriersforbreastcancermetastasistreatment AT weideng advancesinlipidbasednanocarriersforbreastcancermetastasistreatment |